Advances in the field of COX-2 inhibition

Bibliography

• FLETCHER BS, KUJUBU DA, PERRIN DM, HERSCHMAN HR: Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. BiaL Chem. (1992) 267(7):4338–4344.
   PubMedGoogle Scholar
• •Demonstration of the existence of two COX enzymes.
   Google Scholar
• FUNK CD, FUNK LB, KENNEDY ME, PONG AS, FITZGERALD GA: Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB (1991) 5(9):2304–2312.
   PubMed Web of Science ®Google Scholar
• NIWA K, HAENSEL C, ROSS ME, IADECOLA C: Cyclooxygenase-1 participates in selected vasodilator responses of the cerebral circulation. Circ. Res. (2001) 88(6):600–608.
   PubMed Web of Science ®Google Scholar
• SMITH WL, MEADE EA, DEWITT DL: Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann. NY Acad. Li. (1994) 744:50–57.
   PubMed Web of Science ®Google Scholar
• MASFERRER JL, ZWEIFEL BS, MANNING PT et al.:Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc. Natl. Acad. Li. USA (1994) 91(8):3228–3232.
   PubMed Web of Science ®Google Scholar
• PESKAR BM: Role of cyclooxygenase isoforms in gastric mucosal defence. Physiol. Paris. (2001) 95(1-6):3–9.
   PubMedGoogle Scholar
• KOMHOFF M, GRONE HJ, KLEIN T, SEYBERTH HW, NUSING RIVI: Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am. I Physiol. (1997) 272(4 Pt 2):F460–468.
   Google Scholar
• SEIBERT K, ZHANG Y, LEAHY K, HAUSER S, MASFERRER J, ISAKSON P: Distribution of COX-1 and COX-2 in normal and inflamed tissues. Adv. Exp. Med. Biol. (1997) 400A:167–170.
   PubMedGoogle Scholar
• KHAN KN, VENTURINI CM, BUNCH RT etal.: Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal antiinflammatory drug-related nephrotoxicity. Taxied. Pathol. (1998) 26(5):612–620.
   Google Scholar
• CROFFORD LJ: COX-1 and COX-2 tissue expression: implications and predictions. Rheumatol. (1997) 24 (549):15–19.
   Google Scholar
• ARAKAWA T, HIGUCHI K, FUKUDA T, FUJI WARA Y, KOBAYASHI K, KUROKI T: Prostaglandins in the stomach: an update. Castroenterol. (1998) 27 (S1):S1–11.
   Google Scholar
• VANE JR, BAKHLE YS, BOTTING RM: Cyclooxygenases 1 and 2. Ann. Rev Pharmacol. Taxied. (1998) 38:97–120.
   PubMed Web of Science ®Google Scholar
• WALLACE JL: Pathogenesis of NSAID-induced gastroduodenal mucosal injury. Best. Pract. Res. Clin. Gastroenterol (2001) 15(5):691–703.
   PubMed Web of Science ®Google Scholar
• YUCEL-LINDBERG T, AHOLA H, CARLSTEDT-DUKE J, MODEER T: Involvement of tyrosine kinases on cyclooxygenase expression and prostaglandin E2 production in human gingival fibroblasts stimulated with interleukin-lbeta and epidermal growth factor. Biochem. Biophys. Res. Commun. (1999) 257(2):528–532.
   PubMedGoogle Scholar
• SMITH WL, DEWITT DL, GARAVITO RM: Cyclooxygenases: structural, cellular, and molecular biology. Ann. Rev Biochem. (2000) 69:145–182.
   PubMed Web of Science ®Google Scholar
• CROFFORD LJ, WILDER RU, RISTIMAKI AP et al.: Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-113, phorbol ester, and corticosteroids. j OM Invest. (1994) 93(3):1095–1101.
   Google Scholar
• MIFFLIN RC, SAADA JI, DI MARI JF, ADEGBOYEGA PA, VALENTICH JD, POWELL DW: Regulation of COX-2 expression in human intestinal myofibroblasts: mechanisms of IL-1-mediated induction. Am. I Physiol. Cell. Physiol. (2002) 282(4):C824–834.
   Google Scholar
• CAO C, MATSUMURA K, SHIRAKAWA N et al: Pyrogenic cytokines injected into the rat cerebral ventricle induce cyclooxygenase-2 in brain endothelial cells and also upregulate their receptors. Eur. NeuroscL (2001) 13(9):1781–1790.
   PubMedGoogle Scholar
• SAMAD TA, MOORE KA, SAPIRSTEIN A et al.: Interleukin-113-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature (2001) 410(6827):471–475.
   PubMed Web of Science ®Google Scholar
• LOPEZ-URRUTIA L, ALONSO A, BAYON Y, NIETO ML, ORDUNA A, SANCHEZ CRESPO M: Brucella lipopolysaccharides induce cyclooxygenase-2 expression in monocytic cells. Biochem. Biophys. Res. Commun. (2001) 289(2):372–375.
   PubMedGoogle Scholar
• DEVAUX Y, SEGUIN C, GROSJEAN S etal.: Lipopolysaccharide-induced increase of prostaglandin E(2) is mediated by inducible nitric oxide synthase activation of the constitutive cyclooxygenase and induction of membrane-associated prostaglandin E synthase. j Immuriol. (2001) 167(7):3962–3971.
   Google Scholar
• FUTAKI N, TAKAHASHI S, KITAGAWA T, YAMAKAWA Y, TANAKA M, HIGUCHI S: Selective inhibition of cyclooxygenase-2 by NS-398 in endotoxin shock rats in vivo. Inllamm. Res. (1997) 46(12):496–502.
   PubMedGoogle Scholar
• GOPPELT-STRUEBE M, BEICHE F: Cyclooxygenase-2 in the spinal cord: localization and regulation after a peripheral inflammatory stimulus. Adv. Exp. Med. Biol. (1997) 433:213–216.
   PubMedGoogle Scholar
• COFFEY RJ, HAWKEY CJ, DAMSTRUP L et al.: Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc. Nat] Acad. Sci. USA (1997) 94(2):657–662.
   PubMed Web of Science ®Google Scholar
• MITCHELL JA, EVANS TW: Cyclooxygenase-2 as a therapeutic target. Irillamm. Res. (1998) 47 (S2):S88–92.
   Google Scholar
• CAO Y, PRESCOTT SM: Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. j Cell. Physiol. (2002) 190(3):279–286.
   PubMedGoogle Scholar
• CHAN G, BOYLE JO, YANG EK et al: Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer. Res. (1999) 59(5):991–994.
   PubMed Web of Science ®Google Scholar
• PENG JP SU CY, CHANG HC, CHAI CY, HUNG WC: Overexpression of cyclo-oxygenase 2 in squamous cell carcinoma of the hypopharynx. Hum. Pathol. (2002) 33(1):100–104.
   PubMedGoogle Scholar
• HALF E, TANG XM, GWYN K, SAHIN A, WATHEN K, SINICROPE FA: Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res. (2002) 62(6):1676–1681.
   PubMed Web of Science ®Google Scholar
• BRODIE AM, LU Q, LONG BJ et al: Aromatase and COX-2 expression in human breast cancers. j Steroid. Biochem. Ma] Biol. (2001) 79(1-5):41–47.
   PubMed Web of Science ®Google Scholar
• YOSHIMATSU K, ALTORKI NK, GOLIJANIN D et al.: Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. ail Cancer Res. (2001) 7(9):2669–2674.
   Google Scholar
• DANNENBERG AJ, ALTORKI NK, BOYLE JO, LIN DT, SUBBARAMAIAH K: Inhibition of cyclooxygenase-2: an approach to preventing cancer of the upper aerodigestive tract. Ann. NY Acad. Li. (2001) 952:109–115.
   PubMed Web of Science ®Google Scholar
• TAKETO MM: COX-2 and colon cancer.Irillamm. Res. (1998) 47(52):5112–116.
   Google Scholar
• MAEKAWA M, SUGANO K, SANO H et al.: Increased expression of cyclooxygenase-2 to -1 in human colorectal cancers and adenomas, but not in hyperplastic polyps. hilt. J. OM. Oricol. (1998) 28(7):421–426.
   Google Scholar
• NIIJIMA M, YAMAGUCHI T, ISHIHARA T et al: Immunohistochemical analysis and in situ hybridization of cyclooxygenase-2 expression in intraductal papillary-mucinous tumors of the pancreas. Cancer (2002) 94(5):1565–1573.
   PubMedGoogle Scholar
• SPECHT MC, TUCKER ON, HOCEVER M, GONZALEZ D, TENG L, FAHEY TJ 3rd: Cyclooxygenase-2 expression in thyroid nodules. j OM. Eridocrinol. Metab. (2002) 87(1):358–363.
   PubMedGoogle Scholar
• LEE LM, PAN CC, CHENG CJ, CHI CW, LIU TY: Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. Anticancer Res. (2001) 21(2B):1291–1294.
   Google Scholar
• CHAN TA: Nonsteroidal anti-inflammatory drugs, apoptosis and colon cancer chemoprevention. Lancet Oricol. (2002) 3(3):166–174.
   PubMedGoogle Scholar
• LYNCH PM: COX-2 inhibition in clinical cancer prevention. Oncology (Huritingt.) (2001) 15(355):21–26.
   PubMed Web of Science ®Google Scholar
• MASFERRER J: Approach to angiogenesis inhibition based on cyclooxygenase-2. Cancer J. (2001) 7(53):5144–150.
   Google Scholar
• LEAHY KM, KOKI AT, MASFERRER JL: Role of cyclooxygenases in angiogenesis. Curl: Med. Chem. (2000) 7(11):1163–1170.
   PubMed Web of Science ®Google Scholar
• LUKIW WJ, BAZAN NG: Cyclooxygenase 2 RNA message abundance, stability, and hypervariability in sporadic Alzheimer neocortex. I Neurosci. Res. (1997) 50(6)937–945.
   Google Scholar
• CRYER B: Mucosal defense and repair. Role of prostaglandins in the stomach and duodenum. Castroenterol OM. North. Am. (2001) 30(4):877–894.
   PubMedGoogle Scholar
• DEWITT DL: Cox-2-selective inhibitors: the new super aspirins. Ma] Pharmacol (1999) 55(4):625–631.
   PubMedGoogle Scholar
• NEEDLEMAN P, TURK J, JAKSCHIK BA, MORRISON AR, LEFKOWITH JB: Arachidonic acid metabolism. Ann. Rev Biochem. (1986) 55:69–102.
   PubMed Web of Science ®Google Scholar
• OMINI C, MONCADA S, VANE JR: The effects of prostacyclin (PGI2) on tissues which detect prostaglandins (PG S). Prostaglandins (1977) 14(4):625–632.
   PubMedGoogle Scholar
• DOGNE JM, DE LEVAL X, DELARGE J, DAVID JL, MASEREEL B: New trends in thromboxane and prostacyclin modulators. Curr. Med. Chem. (2000) 7(6):609–628.
   PubMedGoogle Scholar
• VAPAATALO H, PARANTAINEN J: Prostaglandins; their biological and pharmacological role. Med. Biol. (1978) 56(4):163–183.
   PubMedGoogle Scholar
• CARSTEN ME: Prostaglandins and oxytocin: their effects on uterine smooth muscle. Prostaglandins (1974) 5(1):33–40.
   PubMedGoogle Scholar
• WEBER PC: Renal prostaglandins, kidney function and essential hypertension. Contrib. Nephrol. (1980) 23:83–92.
   PubMedGoogle Scholar
• GRANGER JP, ALEXANDER BT, LLINAS M: Mechanisms of pressure natriuresis. Curr. Hypertens. Rep. (2002) 4(2):152–159.
   PubMedGoogle Scholar
• TAZAWA R, XU XM, WU KK, WANG LH: Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. Biochem. Biophys. Res. Commun. (1994) 203(1):190–199.
   PubMed Web of Science ®Google Scholar
• KOSAKA T, MIYATA A, IHARA H et al.: Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur. j Biochem. (1994) 221(3):889–897.
   PubMedGoogle Scholar
• YOKOYAMA C, TANABE T: Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme. Biochem. Biophys. Res. Commun. (1989) 165(2):888–894.
   PubMedGoogle Scholar
• KRAEMER SA, MEADE EA, DEWITT DL: Prostaglandin endoperoxide synthase gene structure: identification of the transcriptional start site and 5'-flanking regulatory sequences. Arch. Biochem. Biophys. (1992) 293(2):391–400.
   PubMedGoogle Scholar
• HERSCHMAN HR: Primary response genes induced by growth factors and tumor promoters. Ann. Rev Biochem. (1991) 60:281–319.
   PubMed Web of Science ®Google Scholar
• HERSCHMAN HR: Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer Metastasis Rev (1994) 13(3-4):241–256.
   PubMedGoogle Scholar
• KUJUBU DA, FLETCHER BS, VARNUM BC, LIM RW, HERSCHMAN HR: TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. j Biol. Chem. (1991) 266(20):12866–12872.
   PubMed Web of Science ®Google Scholar
• SHAW G, KAMEN R: A conserved AU sequence from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell (1986) 46(5):659–667.
   PubMedGoogle Scholar
• O'BANION MK, WINN VD, YOUNG DA: cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc. Natl. Acad. Li. USA (1992) 89(11):4888–4892.
   PubMed Web of Science ®Google Scholar
• SHALOM-BARAK T, QUACH J, LOTZ M: Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-icB. j Biol. Chem. (1998) 273(42):27467–27473.
   PubMed Web of Science ®Google Scholar
• IMSEIS HM, ZIMMERMAN PD, SAMUELS P, KNISS DA: Tumour necrosis factor-alpha induces cyclo-oxygenase-2 gene expression in first trimester trophoblasts: suppression by glucocorticoids and NSAIDs. Placenta (1997) 18(7):521–526.
   PubMedGoogle Scholar
• PERKINS DJ, KNISS DA: Tumor necrosis factor-a promotes sustained cyclooxygenase-2 expression: attenuation by dexamethasone and NSAIDs. Prostaglandins (1997) 54(4):727–743.
   PubMed Web of Science ®Google Scholar
• BENNETT PR, MOORE GE: Genetic conservation of cyclo-oxygenase. Prostaglandins (1991) 41(2):135–142.
   PubMedGoogle Scholar
• SMITH WL, GARAVITO RM, DEWITT DL: Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. _J. Biol. Chem. (1996) 271(52):33157–33160.
   PubMed Web of Science ®Google Scholar
• OTTO JC, SMITH WL: The orientation of prostaglandin endoperoxide synthases-1 and -2 in the endoplasmic reticulum. j Biol. Chem. (1994) 269(30:19868–19875.
   PubMedGoogle Scholar
• MURAKAMI M, MATSUMOTO R, AUSTEN KF, ARM JP: Prostaglandin endoperoxide synthase-1 and -2 couple to different transmembrane stimuli to generate prostaglandin D2 in mouse bone marrow-derived mast cells. j Biol. Chem. (1994) 269(35):22269–22275.
   PubMedGoogle Scholar
• GARAVITO RM: The cyclooxygenase-2 structure: new drugs for an old target? Nat. Struct. Biol. (1996) 3(10:897–901.
   Google Scholar
• LOLL PJ, PICOT D, GARAVITO RM: The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat. Struct. Biol. (1995) 2(8):637–643.
   PubMedGoogle Scholar
• LUONG C, MILLER A, BARNETT J, CHOW J, RAMESHA C, BROWNER MF: Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat. Struct. Biol. (1996) 3(10:927–933.
   PubMedGoogle Scholar
• ISEKI S: Immunocytochemical localization of cyclooxygenase-1 and cyclooxygenase-2 in the rat stomach. Ilistochein. j (1995) 27(4):323–328.
   PubMedGoogle Scholar
• •Demonstration of the role of COX-2 in physiological processes.
   Google Scholar
• HARRIS RC, MCKANNA JA, AKAI Y, JACOBSON HR, DUBOIS RN, BREYER MD: Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. j Clin. Invest. (1994) 94(6):2504–2510.
   PubMed Web of Science ®Google Scholar
• •Demonstration of the role of COX-2 in physiological processes.
   Google Scholar
• SLATER D, ALLPORT V, BENNETT P: Changes in the expression of the type-2 but not the type-1 cyclo-oxygenase enzyme in chorion-decidua with the onset of labour. Br. J. Obstet. Gynaecol. (1998) 105(7):745–748.
   PubMedGoogle Scholar
• KURUMBAIL RG, STEVENS AM, GIERSE JK et al.: Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature (1996) 384:644–648.
   PubMed Web of Science ®Google Scholar
• SERVICE RF: Closing in on a stomach-sparing aspirin substitute. Science (1996) 273:1660.
   PubMedGoogle Scholar
• WHITEHOUSE MW: Evaluation of potential antirheumatic drugs in vitro using lymphocytes and epithelial cells. The selective action of indoxole, methyl glyoxal and chloroquine. j Pharm. Pharmacol. (1967) 19(9):590–595.
   Google Scholar
• KAISER DG, GLENN EM, JOHNSON RH, JOHNSTON RL: Correlation of serum indoxole 12,3-bis(p-methoxypheny1)-indolel levels with biologic activity. Pharmacol. Exp. Ther. (1967) 155(1):174–180.
   PubMedGoogle Scholar
• HIGUCHI S, OSADA Y, SHIOIRI Y et al.: Anti-inflammatory activity of a non-steroidal anti-inflammatory agent, oxaprozin, in experimental models. Nippon Yakurigaku Zasshi (1984) 83(5):383–394.
   PubMedGoogle Scholar
• TSUJI K, NAKAMURA K, KONISHI N et al.: Studies on anti-inflammatory agents. IV. Synthesis and pharmacological properties of 1,5-diarylpyrazoles and related derivatives. Chem. Pharm. Bull. (Tokyo) (1997) 45(6):987–999.
   Google Scholar
• PENNING TD, TALLEY JJ, BERTENSHAW SR et al.: Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4- [5-(4-methylpheny1)-3- (trifluoromethyl)-1H-pyrazol-1-yll benze nesulfonamide (SC-58635, celecoxib). I Med. Chem. (1997) 40(9):1347–1365.
   PubMed Web of Science ®Google Scholar
• SEIBERT K, ZHANG Y, LEAHY K et al.: Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc. Nail. Acad. Sci. USA (1994) 91(25):12013–12017.
   PubMed Web of Science ®Google Scholar
• BENSEN WG, ZHAO SZ, BURKE TA et al.: Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. J. Rheurnatal (2000) 27(8):1876–1883.
   PubMedGoogle Scholar
• SILVERSTEIN FE, FAICH G, GOLDSTEIN JL et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA (2000) 284(10):1247–1255.
   Google Scholar
• MCKENNA E BORENSTEIN D, WENDT H, WALLEMARK C, LEFKO WITH JB, GEIS GS: Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scalar/. J. Rheurnatal (2001) 30(1):11–18.
   PubMedGoogle Scholar
• GIMBEL JS, BRUGGER A, ZHAO W, VERBURG KM, GEIS GS: Efficacy and tolerability of celecoxib versus hydrocodone/acetaminophen in the treatment of pain after ambulatory orthopedic surgery in adults. Clin Ther. (2001) 23(2):228–241.
   PubMed Web of Science ®Google Scholar
• NORTH GL: Celecoxib as adjunctive therapy for treatment of colorectal cancer. Ann. Phannacather. (2001) 35(12):1638–1643.
   PubMedGoogle Scholar
• RIENDEAU D, PERCIVAL MD, BRIDEAU C et al.: Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. j Pharrnacal Exp. Ther. (2001) 296:558–566.
   PubMed Web of Science ®Google Scholar
• WEAVER AL: Rofecoxib: clinical pharmacology and clinical experience. arr. Ther. (2001) 23(9):1323–1338.
   Google Scholar
• MATHESON AJ, FIGGITT DP: Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. Drugs (2001) 61(6):833–665.
   PubMedGoogle Scholar
• DETORA LM, KRUPA D, BOLOGNESE J, SPERLING RS, EHRICH EW: Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors. J. Rheurnatal (2001) 28(11):2494–2503.
   PubMedGoogle Scholar
• CAMU E BEECHER T, RECKER DP, VERBURG KM: Valdecoxib, a COX-2-specific inhibitor, is an efficacious, opioid-sparing analgesic in patients undergoing hip arthroplasty. Am.j Ther. (2002) 9(1):43–51.
   PubMedGoogle Scholar
• FRICKE J, VARKAUS J, ZWILLICH S et al.: Valdecoxib is more efficacious than rofecoxib in relieving pain associated with oral surgery. Am.j Ther. (2002) 9(2):89–97.
   PubMedGoogle Scholar
• TALLEY JJ, BROWN DL, CARTER JS et al.: 445-Methy1-3-phenylisoxazol 4 yll benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J. Med. Chem. (2000) 43(5):775–777.
   PubMed Web of Science ®Google Scholar
• HARRIS SI, KUSS M, HUBBARD RC, GOLDSTEIN JL: Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo. Clin. Ther. (2001) 23(9):1422–1428.
   PubMedGoogle Scholar
• LIM H, PARIA BC, DAS SK et al: Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell (1997) 91(2):197–208.
   PubMed Web of Science ®Google Scholar
• ROCCA B, SPAIN LM, CIABATTONI G, PATRONO C, FITZGERALD GA: Differential expression and regulation of cyclooxygenase isozymes in thymic stromal cells. J. Inilnurial (1999) 162(8):4589–4597.
   Google Scholar
• ROCCA B, SPAIN LM, PUREE, LANGENBACH R, PATRONO C, FITZGERALD GA: Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. J. arr. Invest. (1999) 103(10):1469–1477.
   PubMedGoogle Scholar
• HARRIS RC, BREYER MD: Physiologicalregulation of cyclooxygenase-2 in the kidney. Am.j Physial Renal. Physial (2001) 281(1):F1–11.
   Google Scholar
• ROBERTSON RP: Dominance of cyclooxygenase-2 in the regulation of pancreatic islet prostaglandin synthesis. Diabetes (1998) 47(9):1379–1383.
   PubMed Web of Science ®Google Scholar
• BREDER CD, DEWITT D, KRAIG RP: Characterization of inducible cyclooxygenase in rat brain. J. Camp. Neural (1995) 355(2):296–315.
   PubMedGoogle Scholar
• NAKAO S, OGATA Y, SHIMIZU-SASAKI E, YAMAZAKI M, FURUYAMA S, SUGIYA H: Activation of NFicB is necessary for IL-13-induced cyclooxygenase-2 (COX-2) expression in human gingival fibroblasts. Mal Cell. Biachern. (2000) 209(1-2):113–118.
   PubMedGoogle Scholar
• GORGONI B, CAIVANO M, ARIZMENDI C, POLI V: The transcription factor C/EBPP is essential for inducible expression of the cox-2 gene in macrophages but not in fibroblasts. I Biol. Chem. (2001) 276(44):40769–40777.
   Web of Science ®Google Scholar
• MESTRE JR, MACKRELL PJ, RIVADENEIRA DE, STAPLETON PP, TANABE T, DALY JM: Redundancy in the signaling pathways and promoter elements regulating cyclooxygenase-2 gene expression in endotoxin-treated macrophage/ monocytic cells. J. Bid. Chem. (2001) 276(6):3977–3982.
   PubMedGoogle Scholar
• GILROY DW, TOMLINSON A, WILLOUGHBY DA: Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation. Eur. j Pharrnacal (1998) 355(2-3):211–217.
   PubMedGoogle Scholar